Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

A rare case of free bowel perforation associated with infliximab treatment for stricturing Crohn's disease.

Lim CS, Moon W, Park SJ, Park MI, Kim HH, Kim JB, Choi JM, Chang HK, Lee SH.

Korean J Gastroenterol. 2013 Sep;62(3):169-73. Review.

2.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
3.

Bowel Perforation Associated With Infliximab Use in a Pediatrics Patient.

Joshi A, Bajwa R, Bhattacharjee N, Bodicharla R.

WMJ. 2016 Apr;115(2):90-2.

4.

Transcending conventional therapies: the role of biologic and other novel therapies.

Sandborn WJ.

Inflamm Bowel Dis. 2001 May;7 Suppl 1:S9-16. Review.

PMID:
11380043
5.

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.

Aliment Pharmacol Ther. 2005 Oct 1;22(7):613-26.

6.

[A case of psoriasis induced by infliximab treatment for Crohn's disease].

Jwa YJ, Kim NH, Park HJ, Park JS, Bae WK, Kim KA, Lee JS, Moon YS.

Korean J Gastroenterol. 2010 Nov;56(5):324-8. Korean.

7.

[Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].

Lee KM, Kim JS, Shin DH, Cheong JY, Yoo BM, Kim JK, Lee KJ, Hahm KB, Kim JH, Cho SW.

Korean J Gastroenterol. 2004 Nov;44(5):259-66. Korean.

8.

Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease.

Hukkinen M, Pakarinen MP, Piekkala M, Koivusalo A, Rintala R, Kolho KL.

J Crohns Colitis. 2014 Aug;8(8):756-62. doi: 10.1016/j.crohns.2014.01.001. Epub 2014 Jan 18.

PMID:
24447625
9.

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.

Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA.

BMJ Open. 2014 Dec 18;4(12):e005887. doi: 10.1136/bmjopen-2014-005887.

10.

Buccal localization of Crohn's disease with long-term infliximab therapy: a case report.

Ciacci C, Bucci C, Zingone F, Iovino P, Amato M.

J Med Case Rep. 2014 Nov 30;8:397. doi: 10.1186/1752-1947-8-397. Review.

11.

Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.

Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O, Rutgeerts P, Vermeire S, Aerden I, Oortwijn A, Ochsenkühn T.

J Crohns Colitis. 2013 Dec;7(12):950-7. doi: 10.1016/j.crohns.2013.01.011. Epub 2013 Feb 12.

PMID:
23411006
12.

[Anti-TNF therapy in treatment of luminal Crohn's disease].

Marko B, Prka L.

Acta Med Croatica. 2013 Apr;67(2):179-89. Review. Croatian.

PMID:
24471301
13.

Clinical outcome of Crohn's disease treated with infliximab.

Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tözün N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dökmeci A.

Hepatogastroenterology. 2003 Jul-Aug;50(52):952-6.

PMID:
12845957
14.

Infliximab-induced psoriasis during therapy for Crohn's disease.

Steinwurz F, Denadai R, Saad-Hossne R, Queiroz ML, Teixeira FV, Romiti R.

J Crohns Colitis. 2012 Jun;6(5):610-6. doi: 10.1016/j.crohns.2011.12.007. Epub 2012 Jan 26.

PMID:
22398095
15.

Remicade does not abolish the need for surgery in fistulizing Crohn's disease.

Poritz LS, Rowe WA, Koltun WA.

Dis Colon Rectum. 2002 Jun;45(6):771-5.

PMID:
12072629
16.

[Indications and results of infliximab in Crohn's disease].

Karoui S, Boubaker J, Filali A.

Tunis Med. 2004 Dec;82(12):1057-63. Review. French.

PMID:
15822505
18.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
19.

Treatment of luminal and fistulizing Crohn's disease with infliximab.

Comerford LW, Bickston SJ.

Gastroenterol Clin North Am. 2004 Jun;33(2):387-406, xi. Review.

PMID:
15177545
20.

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ.

Gastroenterology. 1999 Oct;117(4):761-9.

PMID:
10500056

Supplemental Content

Support Center